 This current study will enroll EBC subjects with differing breast cancer BC subtypes, with the intent of characterizing the molecular alterations in BC tissue before and after short-term exposure to the anti-androgen ODM-201. Studying the biological mechanisms in which ODM-201 targets the androgen receptor AR in BC will be crucial in understanding its potential role, as well as provide the foundation for further development of ODM-201 in this disease. 